|1.||Griñán, Tania: 2 articles (01/2014 - 03/2012)|
|2.||Pérez, Arlenis: 2 articles (01/2014 - 03/2012)|
|3.||Soto, Yosdel: 2 articles (01/2014 - 03/2012)|
|4.||Martínez-Sánchez, Gregorio: 2 articles (02/2013 - 01/2012)|
|5.||Noa, Miriam: 2 articles (03/2012 - 09/2005)|
|6.||Kuss, Navina: 1 article (01/2015)|
|7.||Hudalla, Hannes: 1 article (01/2015)|
|8.||Poeschl, Johannes: 1 article (01/2015)|
|9.||Braach, Natascha: 1 article (01/2015)|
|10.||Buschmann, Kirsten: 1 article (01/2015)|
03/01/1996 - "At the 11th day, lipofundin was injected intraperitoneally for 8 days to induce formation of foam cells in the granuloma. "
09/01/2005 - "Previous studies have shown that policosanol prevents lipofundin-induced atherosclerotic lesions in rabbits and rats, including foam cell formation, as well as the development of foam cells in carrageenan-induced granulomas in rats. "
09/01/2007 - "Policosanol is a cholesterol-lowering drug isolated from sugar cane wax with concomitant antiplatelet effects that prevents lipofundin-induced atherosclerotic lesions in rabbits and rats, including foam cell formation, and also reduces foam cell formation in carrageenan-induced granulomas in rats, while it inhibits proliferation of smooth muscle cells induced in rabbit cuffed artery. "
04/01/1986 - "[Recent studies on a lipofundin-induced arteriosclerosis model]."
01/01/1987 - "The Lipofundin arteriosclerosis model developed in our laboratory is present together with the mechanism of development of sclerotic vascular lesions and the primary role of permeability changes in the whole process. "
04/01/1986 - "[Arteriosclerosis developing in rabbits after lipofundin administration]."
|3.||Gastrointestinal Diseases (Functional Gastrointestinal Disorders)
06/01/2012 - "Sixty-four adult patients with gastrointestinal diseases were randomly assigned to receive isocaloric and isonitrogenous total parenteral nutrition with an ω-3 fatty acid-enriched emulsion (Lipoplus; study group, n = 32) or medium-chain triacylglycerols/long-chain triacylglycerols (Lipofundin; control group, n = 32) for 5 d after surgery. "
01/01/2014 - "Atherosclerosis was induced in NZW rabbits (n = 14) by the administration of Lipofundin 20% using PBS-receiving animals as control (n = 8). "
03/01/2012 - "Moreover, subcutaneous immunization of New Zealand White rabbits (n=19) with chP3R99 mAb (100 μg, 3 doses at weekly intervals) prevented Lipofundin-induced atherosclerosis (2 mL/kg, 8 days) with a 22-fold reduction in the intima-media ratio (P<0.01). "
01/01/2012 - "Due to the importance of these phenomena as risk factors for atherogenesis, we suggest that Lipofundin induces atherosclerosis mainly through these mechanisms."
07/01/1981 - "Considering the above mentioned facts Lipofundin model seems to be particularly useful for testing medicaments used in the therapy of atherosclerosis."
|5.||Body Weight (Weight, Body)
01/01/2002 - "All the rats were fasted with water ad libitum for 10 h before 0.3 g/kg body weight of 10% Intralipid (LCT) or 10% Lipofundin (MCT: LCT = 50:50) was injected as a bolus to them via the tail vein. "
03/01/1988 - "We performed this test (0.1 g lipid/kg body weight) in 18 young healthy volunteers (nine females and nine males) using Lipofundin MCT 10% (50% MCT; egg phospholipids as emulsifier). "
03/01/1994 - "To determine the hydrolysis rate of medium-chain triglycerides (MCTs) to medium-chain free fatty acids (MCFAs) and the disposition rate of MCFAs, five healthy volunteers (H) and eight surgically stressed patients (S) received 0.5 mL of Lipofundin 20% per kilogram body weight as an intravenous bolus. "
|4.||phospholipid emulsion soybean oil (Intralipid)
|8.||Ouabain (G Strophanthin)
|9.||Nonesterified Fatty Acids (NEFA)
|1.||Total Parenteral Nutrition